

SB 404-1  
(LC 968)  
2/7/23 (SCT/ps)

Requested by Senator PATTERSON

**PROPOSED AMENDMENTS TO  
SENATE BILL 404**

1 In line 2 of the printed bill, after “drugs” insert “; creating new pro-  
2 visions; and amending ORS 646A.689, 646A.693, 646A.694, 646A.695, 705.146  
3 and 743.025”.

4 Delete lines 4 through 8 and insert:

5 **“SECTION 1. Sections 2 and 3 of this 2023 Act are added to and  
6 made a part of the Insurance Code.**

7 **“SECTION 2. (1) As used in this section:**

8 **“(a) ‘Carrier’ has the meaning given that term in ORS 743B.005.**

9 **“(b) ‘Enrollee’ has the meaning given that term in ORS 743B.005.**

10 **“(c) ‘Group purchasing organization’ has the meaning given that  
11 term by the Department of Consumer and Business Services by rule.**

12 **“(d) ‘Health benefit plan’ has the meaning given that term in ORS  
13 743B.005.**

14 **“(e) ‘Pharmacy benefit’ has the meaning given that term in ORS  
15 735.530.**

16 **“(f) ‘Pharmacy benefit manager’ has the meaning given that term  
17 in ORS 735.530.**

18 **“(2) Not later than March 1 of each year, a pharmacy benefit man-  
19 ager registered under ORS 735.532 and a group purchasing organization  
20 operating in this state shall file a report with the Department of  
21 Consumer and Business Services. The report must contain, for the**

1 immediately preceding calendar year, the aggregated dollar amount  
2 of rebates, fees, price protection payments and any other payments the  
3 pharmacy benefit manager or group purchasing organization received  
4 from manufacturers:

5 “(a) Related to managing pharmacy benefits for carriers issuing  
6 health benefit plans in this state; and

7 “(b) That were passed on to:

8 “(A)(i) Carriers issuing health benefit plans in this state; or

9 “(ii) Enrollees at the point of sale of a prescription drug in this  
10 state; or

11 “(B) Retained as revenue by the pharmacy benefit manager or  
12 group purchasing organization.

13 “(3) A report prepared and submitted pursuant to subsection (2) of  
14 this section may not include:

15 “(a) The identity of a carrier or an enrollee;

16 “(b) The price charged for a specific prescription drug or class of  
17 prescription drugs; or

18 “(c) The amount of a rebate or fee provided for a specific drug or  
19 class of prescription drugs.

20 “(4) Except as provided in subsection (5) of this section and ORS  
21 705.137, the information reported to the department under subsection  
22 (2) of this section is confidential and is not subject to disclosure.

23 “(5) Not later than July 1 of each year, the department shall pub-  
24 lish, on a website operated by or on behalf of the department, aggre-  
25 gated data from the reports received under subsection (2) of this  
26 section. The department shall ensure that the aggregated data is pub-  
27 lished in a manner that does not disclose confidential information of  
28 a pharmacy benefit manager or a group purchasing organization.

29 **“SECTION 3. Not later than March 15, a nonprofit organization that**  
30 **advocates on behalf of patients in this state shall annually submit to**

1 the Department of Consumer and Business Services, in the manner  
2 prescribed the department, the following information for the imme-  
3 diately preceding calendar year:

4 “(1) The payments, donations, subsidies and other contributions,  
5 and amount of each payment, donation, subsidy or other contribution,  
6 provided to the nonprofit organization by a third party, including but  
7 not limited to a manufacturer or a pharmacy benefit manager, as de-  
8 fined in ORS 735.530; and

9 “(2) The percentage of the nonprofit organization’s annual gross  
10 income attributable to payments, donations, subsidies or other con-  
11 tributions from each third party.

12 “SECTION 4. ORS 646A.680, 646A.683, 646A.686, 646A.689, 646A.692,  
13 646A.696 and 646A.697 are added to and made a part of ORS 646A.693  
14 to 646A.695.

15 “SECTION 5. ORS 646A.689 is amended to read:

16 “646A.689. (1) As used in [*this section and*] ORS 646A.693 to 646A.695:

17 “(a) ‘Drug’ has the meaning given that term in ORS 689.005.

18 “(b) ‘Health care facility’ has the meaning given that term in ORS 442.015.

19 “(c) ‘Health care service contractor’ has the meaning given that term in  
20 ORS 750.005.

21 “(d)(A) ‘Manufacture’ means:

22 “(i) The production, preparation, propagation, compounding, conversion  
23 or processing of a drug, either directly or indirectly by extraction from sub-  
24 stances of natural origin or independently by means of chemical synthesis,  
25 or by a combination of extraction and chemical synthesis; and

26 “(ii) The packaging or repackaging of a drug or labeling or relabeling of  
27 a drug container.

28 “(B) ‘Manufacture’ does not include the preparation or compounding of  
29 a drug by an individual for the individual’s own use or the preparation,  
30 compounding, packaging or labeling of a drug:

1       “(i) By a health care practitioner incidental to administering or dispensing a drug in the course of professional practice;

3       “(ii) By a health care practitioner or at the practitioner’s authorization and supervision for the purpose of or incidental to research, teaching or chemical analysis activities and not for sale;

6       “(iii) By a health care service contractor for dispensing to a subscriber or delivery to a health care facility or outpatient clinic owned or operated by the health care service contractor or an affiliate of the health care service contractor;

10       “(iv) By a centralized repackaging operation for distribution to subscribers of health care service contractors or to pharmacies, health care facilities or outpatient clinics operated by or affiliated with a health care service contractor; or

14       “(v) By a health care facility for dispensing to a patient or other person.

15       “(e) ‘Manufacturer’ means a person that manufactures a prescription drug that is sold in this state.

17       “(f) ‘New prescription drug’ has the meaning prescribed by the Department of Consumer and Business Services by rule.

19       “(g) ‘Patient assistance program’ means a program that a manufacturer offers to the general public in which a consumer may reduce the consumer’s out-of-pocket costs for prescription drugs by using coupons or discount cards, receiving copayment assistance or by other means.

23       “(h) ‘Prescription drug’ means a drug that must:

24       “(A) Under federal law, be labeled ‘Caution: Federal law prohibits dispensing without prescription’ prior to being dispensed or delivered; or

26       “(B) Under any applicable federal or state law or regulation, be dispensed only by prescription or restricted to use only by health care practitioners.

28       “(i) ‘Price’ means the wholesale acquisition cost as defined in 42 U.S.C. 1395w-3a(c)(6)(B).

30       “(2) No later than March 15 of each year, a manufacturer shall report the

1 information described in subsection (3) of this section to the department re-  
2 garding each prescription drug for which:

3 “(a) The price was \$100 or more for a one-month supply or for a course  
4 of treatment lasting less than one month; and

5 “(b) There was a net increase of 10 percent or more in the price of the  
6 prescription drug described in paragraph (a) of this subsection over the  
7 course of the previous calendar year.

8 “(3) For each prescription drug described in subsection (2) of this section,  
9 a manufacturer shall report to the department, in the form and manner pre-  
10 scribed by the department:

11 “(a) The name and price of the prescription drug and the net increase,  
12 expressed as a percentage, in the price of the drug over the course of the  
13 previous calendar year;

14 “(b) The length of time the prescription drug has been on the market;

15 “(c) The factors that contributed to the price increase;

16 “(d) The name of any generic version of the prescription drug available  
17 on the market;

18 “(e) The research and development costs associated with the prescription  
19 drug that were paid using public funds;

20 “(f) The direct costs incurred by the manufacturer:

21 “(A) To manufacture the prescription drug;

22 “(B) To market the prescription drug;

23 “(C) To distribute the prescription drug; and

24 “(D) For ongoing safety and effectiveness research associated with the  
25 prescription drug;

26 “(g) The total sales revenue for the prescription drug during the previous  
27 calendar year;

28 “(h) The manufacturer’s profit attributable to the prescription drug dur-  
29 ing the previous calendar year;

30 “(i) The introductory price of the prescription drug when it was approved

1 for marketing by the United States Food and Drug Administration and the  
2 net yearly increase, by calendar year, in the price of the prescription drug  
3 during the previous five years;

4 “(j) The 10 highest prices paid for the prescription drug during the pre-  
5 vious calendar year in any country other than the United States;

6 “(k) Any other information that the manufacturer deems relevant to the  
7 price increase described in subsection (2)(b) of this section; and

8 “(L) The documentation necessary to support the information reported  
9 under this subsection.

10 “(4) The department may use any prescription drug price information the  
11 department deems appropriate to verify that manufacturers have properly  
12 reported price increases as required by subsections (2) and (3) of this section.

13 “(5) **No later than March 15 of each year**, a manufacturer shall [*ac-*  
14 *company the*], **in addition to the information required under subsection**  
15 **(2) of this section**, report [*provided under subsection (2) of this section*  
16 *with*] the following information about each patient assistance program of-  
17 fered **or funded** by the manufacturer **that provided assistance** to consum-  
18 ers residing in this state [*for the prescription drugs described in subsection*  
19 *(2) of this section*] **during the previous calendar year:**

20 “(a) The number of consumers who participated in the program;

21 “(b) The total value of the coupons, discounts, copayment assistance or  
22 other reduction in costs provided to consumers in this state who participated  
23 in the program;

24 “(c) For each drug, the number of refills that qualify for the program, if  
25 applicable;

26 “(d) If the program expires after a specified period of time, the period of  
27 time that the program is available to each consumer; and

28 “(e) The eligibility criteria for the program and how eligibility is verified  
29 for accuracy.

30 “(6) No later than 30 days after a manufacturer introduces a new pre-

1 prescription drug for sale in the United States at a price that exceeds the  
2 threshold established by the Centers for Medicare and Medicaid Services for  
3 specialty drugs in the Medicare Part D program, the manufacturer shall no-  
4 tify the department, in the form and manner prescribed by the department,  
5 of all the following information:

6 “(a) A description of the marketing used in the introduction of the new  
7 prescription drug;

8 “(b) The methodology used to establish the price of the new prescription  
9 drug;

10 “(c) Whether the United States Food and Drug Administration granted  
11 the new prescription drug a breakthrough therapy designation or a priority  
12 review;

13 “(d) If the new prescription drug was not developed by the manufacturer,  
14 the date of and the price paid for acquisition of the new prescription drug  
15 by the manufacturer;

16 “(e) The manufacturer’s estimate of the average number of patients who  
17 will be prescribed the new prescription drug each month; and

18 “(f) The research and development costs associated with the new pre-  
19 scription drug that were paid using public funds.

20 “(7)(a) After receiving the report or information described in subsections  
21 (2), (3), (5) or (6) of this section, the department may make a written request  
22 to the manufacturer for supporting documentation or additional information  
23 concerning the report. The department shall prescribe by rule the periods:

24 “(A) Following the receipt of the report or information during which the  
25 department may request additional information; and

26 “(B) Following a request by the department for additional information  
27 during which a manufacturer may respond to the request.

28 “(b) The department may extend the period prescribed under paragraph  
29 (a)(B) of this subsection, as necessary, on a case-by-case basis.

30 “(8) A manufacturer may be subject to a civil penalty, as provided in ORS

1 646A.692, for:

2 “(a) Failing to submit timely reports or notices as required by this sec-  
3 tion;

4 “(b) Failing to provide information required under this section;

5 “(c) Failing to respond in a timely manner to a written request by the  
6 department for additional information under subsection (7) of this section;  
7 or

8 “(d) Providing inaccurate or incomplete information under this section.

9 “(9) Except as provided in subsection (10) of this section, the department  
10 shall post to its website all of the following information:

11 “(a) A list of the prescription drugs reported under subsection (2) of this  
12 section and the manufacturers of those prescription drugs;

13 “(b) Information reported to the department under subsections (3) and (5)  
14 to (7) of this section; and

15 “(c) Written requests by the department for additional information under  
16 subsection (7) of this section.

17 “(10)(a) The department may not post to its website any information de-  
18 scribed in subsection (9) of this section if:

19 “(A) The information is conditionally exempt from disclosure under ORS  
20 192.345 as a trade secret; and

21 “(B) The public interest does not require disclosure of the information.

22 “(b) If the department withholds any information from public disclosure  
23 pursuant to this subsection, the department shall post to its website a report  
24 describing the nature of the information and the department’s basis for  
25 withholding the information from disclosure.

26 “(c) A person may petition the Attorney General, as provided in ORS  
27 192.411, to review a decision by the department to withhold information  
28 pursuant to paragraph (a) of this subsection.

29 “(11) In accordance with ORS 646A.694, the department shall provide to  
30 the Prescription Drug Affordability Board established in ORS 646A.693:



1 “(a) Each calendar quarter, a list of prescription drugs included in reports  
2 submitted under subsections (2) and (6) of this section; and

3 “(b) Access to pricing information submitted to the department under  
4 subsections (3), (6) and (7) of this section.

5 “(12) The department shall make available to consumers, online and by  
6 telephone, a process for consumers to notify the department about an in-  
7 crease in the price of a prescription drug. **Any personally identifiable**  
8 **information about a consumer obtained by the department through a**  
9 **notification under this subsection, including but not limited to a**  
10 **consumer’s name, address, telephone number and electronic mail ad-**  
11 **dress, is confidential and not subject to disclosure.**

12 “(13) The department may adopt rules as necessary for carrying out the  
13 provisions of this section[, *including but not limited to rules establishing fees*  
14 *to be paid by manufacturers to be used solely to pay the costs of the department*  
15 *in carrying out the provisions of this section*].

16 “(14) No later than December 15 of each year, the department shall com-  
17 pile and report the information collected by the department under this sec-  
18 tion to the interim committees of the Legislative Assembly related to health.  
19 The report shall include recommendations for legislative changes, if any, to  
20 contain the cost of prescription drugs and reduce the impact of price in-  
21 creases on consumers, the Department of Corrections, the Public Employees’  
22 Benefit Board, the Oregon Health Authority, the Department of Human  
23 Services, the Oregon Educators Benefit Board and health insurance premi-  
24 ums in the commercial market.

25 **“SECTION 6.** ORS 646A.693 is amended to read:

26 “646A.693. (1) The Prescription Drug Affordability Board is established in  
27 the Department of Consumer and Business Services to protect residents of  
28 this state, state and local governments, commercial health plans, health care  
29 providers, pharmacies licensed in this state and other stakeholders within  
30 the health care system in this state from the high costs of prescription drugs.

1       “(2) The board consists of [*five*] **eight** members [*and three alternates*] ap-  
2 pointed by the Governor.

3       “(3) The term of office of each member of the board is four years, but a  
4 member serves at the pleasure of the Governor. Before the expiration of the  
5 term of a member, the Governor shall appoint a successor whose term begins  
6 on January 1 next following. A member is eligible for reappointment. If there  
7 is a vacancy for any cause, the Governor shall make an appointment to be-  
8 come immediately effective for the unexpired term.

9       “(4) The appointment of each member of the board is subject to confir-  
10 mation by the Senate in the manner prescribed in ORS 171.562 and 171.565.

11       “(5) A member of the board is entitled to compensation and expenses as  
12 provided in ORS 292.495.

13       “(6) The members of the board must be residents of this state with ex-  
14 pertise in health care economics and clinical medicine.

15       “(7) A member of the board may not be an employee of, a board member  
16 of or a consultant to a manufacturer or a trade association of manufacturers.

17       “(8) The board shall select one of its members as chairperson and another  
18 as vice chairperson, for terms and with duties and powers necessary for the  
19 performance of the functions of the offices as the board determines.

20       “(9) A majority of the members of the board constitutes a quorum for the  
21 transaction of business.

22       “(10) The department shall appoint an executive director for the board,  
23 may employ consultants, investigators or other staff and shall provide staff  
24 support to the board to carry out its duties.

25       “(11) The board shall meet at least once every six weeks at a time and  
26 place determined by the chairperson. The chairperson may cancel or postpone  
27 a regular meeting if there is no prescription drug to review. The board may  
28 also meet at other times and places specified by the call of the chairperson  
29 or of a majority of the members of the board.

30       “(12)(a) The following actions by the board shall be open to the public in

1 accordance with ORS 192.610 to 192.690:

2 “(A) Any deliberation on whether to conduct an affordability review of  
3 a prescription drug under ORS 646A.695; and

4 “(B) Any decision or deliberation toward a decision on any matter before  
5 the board except as provided in paragraph (b) of this subsection.

6 “(b) The board may meet in executive session to discuss trade secret in-  
7 formation.

8 “(13) The board shall:

9 “(a) Provide public notice of each board meeting at least two weeks in  
10 advance of the meeting;

11 “(b) Make materials for each board meeting available to the public at  
12 least one week in advance of the meeting;

13 “(c) Provide an opportunity for public comment at each open meeting of  
14 the board; and

15 “(d) Provide the public with the opportunity to submit written comments  
16 on any pending decision of the board.

17 “(14) The board may allow expert testimony at board meetings, including  
18 when the board meets in executive session.

19 “(15)(a) A member of the board shall recuse the member from decisions  
20 related to a prescription drug if the member, or an immediate family member  
21 of the member, has received or could receive any of the following:

22 “(A) A direct financial benefit of any amount deriving from the result or  
23 finding of a study, review or determination by or for the board; or

24 “(B) A financial benefit from any person that owns, manufactures, or  
25 provides prescription drugs, services or items to be reviewed by the board  
26 that in the aggregate exceeds \$5,000 per year.

27 “(b) For the purposes of paragraph (a) of this subsection, a financial  
28 benefit includes honoraria, fees, stock, the value of the member’s or imme-  
29 diate family member’s stock holdings and any direct financial benefit deriv-  
30 ing from the result or finding of a study, review or determination by or for

1 the board.

2 “(c) A conflict of interest shall be disclosed:

3 “(A) By the board when hiring board staff;

4 “(B) By the Governor when appointing members [*and alternate members*]  
5 to the board; and

6 “(C) By the board, when a member of the board is recused in any final  
7 decision resulting from a review of a prescription drug.

8 “(d) A conflict of interest shall be disclosed at the earlier of:

9 “(A) Prior to the first board meeting after the conflict is identified; or

10 “(B) Within five days after the conflict is identified.

11 “(e) A conflict of interest disclosed under this section shall be posted on  
12 the website of the board unless the chairperson of the board recuses the  
13 member from any final decision resulting from a review of a prescription  
14 drug.

15 “(f) A posting under paragraph (e) of this subsection shall include the  
16 type, nature and magnitude of the conflict of interest of the member in-  
17 volved.

18 “(16) Members [*and alternate members*] of the board, staff and third par-  
19 ties that contract with the board may not accept any gift or donation of  
20 services or property that creates a potential conflict of interest or has the  
21 appearance of biasing the work of the board.

22 “(17)(a) The board may enter into a contract with a qualified, independent  
23 third party for any service necessary to carry out the powers and duties of  
24 the board.

25 “(b) Unless permission is granted by the board, a third party hired by the  
26 board may not release, publish or otherwise use any information to which  
27 the third party has access under its contract.

28 “(18) In accordance with applicable provisions of ORS chapter 183, the  
29 board may adopt rules necessary for the administration of ORS 646A.693 to  
30 646A.695.

1        **“SECTION 7.** ORS 646A.694 is amended to read:

2        “646A.694. (1) The Department of Consumer and Business Services shall  
3 provide to the Prescription Drug Affordability Board each calendar quarter  
4 a list of prescription drugs included in reports submitted to the department  
5 under ORS 646A.689 (2) and (6), a list of drugs included in reports submitted  
6 to the department under ORS **646A.683 and** 743.025 and a list of insulin  
7 drugs marketed in this state during the previous calendar year. Each cal-  
8 endar year, the board shall identify nine drugs and at least one insulin  
9 product from the lists provided under this subsection that the board deter-  
10 mines may create affordability challenges for health care systems or high  
11 out-of-pocket costs for patients in this state based on criteria adopted by the  
12 board by rule, including but not limited to:

13        “(a) Whether the prescription drug has led to health inequities in com-  
14 munities of color;

15        “(b) The number of residents in this state prescribed the prescription  
16 drug;

17        “(c) The price for the prescription drug sold in this state;

18        “(d) The estimated average monetary price concession, discount or rebate  
19 the manufacturer provides to health insurance plans in this state or is ex-  
20 pected to provide to health insurance plans in this state, expressed as a  
21 percentage of the price for the prescription drug under review;

22        “(e) The estimated total amount of the price concession, discount or re-  
23 bate the manufacturer provides to each pharmacy benefit manager registered  
24 in this state for the prescription drug under review, expressed as a percent-  
25 age of the prices;

26        “(f) The estimated price for therapeutic alternatives to the drug that are  
27 sold in this state;

28        “(g) The estimated average price concession, discount or rebate the man-  
29 ufacturer provides or is expected to provide to health insurance plans and  
30 pharmacy benefit managers in this state for therapeutic alternatives;

1 “(h) The estimated costs to health insurance plans based on patient use  
2 of the drug consistent with the labeling approved by the United States Food  
3 and Drug Administration and recognized standard medical practice;

4 “(i) The impact on patient access to the drug considering standard pre-  
5 scription drug benefit designs in health insurance plans offered in this state;

6 “(j) The relative financial impacts to health, medical or social services  
7 costs as can be quantified and compared to the costs of existing therapeutic  
8 alternatives;

9 “(k) The estimated average patient copayment or other cost-sharing for  
10 the prescription drug in this state;

11 “(L) Any information a manufacturer chooses to provide; and

12 “(m) Any other factors as determined by the board in rules adopted by the  
13 board.

14 “(2) A drug that is designated by the Secretary of the United States Food  
15 and Drug Administration, under 21 U.S.C. 360bb, as a drug for a rare disease  
16 or condition is not subject to review under subsection (1) of this section.

17 “(3) The board shall accept testimony from patients and caregivers af-  
18 fected by a condition or disease that is treated by a prescription drug under  
19 review by the board and from individuals with scientific or medical training  
20 with respect to the disease or condition.

21 “(4)(a) If the board considers the cost-effectiveness of a prescription drug  
22 in criteria adopted by the board under subsection (1) of this section, the  
23 board may not use quality-adjusted life-years, or similar formulas that take  
24 into account a patient’s age or severity of illness or disability, to identify  
25 subpopulations for which a prescription drug would be less cost-effective. For  
26 any prescription drug that extends life, the board’s analysis of cost-  
27 effectiveness must weigh the value of the quality of life equally for all pa-  
28 tients, regardless of the patients’ age or severity of illness or disability.

29 “(b) As used in this subsection:

30 “(A) ‘Health utility’ means a measure of the degree to which having a

1 particular form of disease or disability or having particular functional limi-  
2 tations negatively impacts the quality of life as compared to a state of per-  
3 fect health, expressed as a number between zero and one.

4 “(B) ‘Quality-adjusted life-year’ is the product of a health utility multi-  
5 plied by the extra months or years of life that a patient might gain as a re-  
6 sult of a treatment.

7 “(5) To the extent practicable, the board shall access pricing information  
8 for prescription drugs by:

9 “(a) Accessing pricing information collected by the department under ORS  
10 646A.689 and 743.025;

11 “(b) Accessing data reported to the Oregon Health Authority under ORS  
12 442.373;

13 “(c) Entering into a memorandum of understanding with another state to  
14 which manufacturers already report pricing information; and

15 “(d) Accessing other publicly available pricing information.

16 “(6) The information used to conduct an affordability review may include  
17 any document and research related to the introductory price or price in-  
18 crease of a prescription drug, including life cycle management, net average  
19 price in this state, market competition and context, projected revenue and  
20 the estimated value or cost-effectiveness of the prescription drug.

21 “(7)(a) **For the prescription drugs that were subject to affordability**  
22 **reviews, the board may establish upper payment limits, based upon**  
23 **criteria prescribed by the board by rule, on the price paid for the pre-**  
24 **scription drugs by:**

25 “(A) **A public body, as defined in ORS 174.109;**

26 “(B) **The Oregon Health Authority for enrollees in the state medical**  
27 **assistance program or by coordinated care organizations, as defined in**  
28 **ORS 414.025, for members of the coordinated care organizations;**

29 “(C) **The Public Employees’ Benefit Board or the Oregon Educators**  
30 **Benefit Board in self-insured plans offered by the boards or by**

1 insurer’s for enrollees in health benefit plans offered by the boards;

2 “(D) The Oregon State Hospital;

3 “(E) State or local correctional facilities; and

4 “(F) Student health clinics at institutions of higher education in  
5 this state.

6 “(b) The Prescription Drug Affordability Board shall monitor the  
7 availability of any prescription drug for which the board established  
8 an upper payment limit and if there becomes a shortage of the pre-  
9 scription drug, the board shall evaluate whether the upper payment  
10 limit should be modified or suspended.

11 “(c) An upper payment limit established by the board is suspended  
12 on any prescription drug while the drug is identified as currently in  
13 shortage on the drug shortage database maintained by the United  
14 States Food and Drug Administration.

15 “[~~(7)~~] (8) The department and the board shall keep strictly confidential  
16 any information collected, used or relied upon for the review conducted un-  
17 der this section if the information is:

18 “(a) Information submitted to the department by a manufacturer under  
19 ORS 646A.689; and

20 “(b) Confidential, proprietary or a trade secret as defined in ORS 192.345.

21 **“SECTION 8.** ORS 646A.695 is amended to read:

22 “646A.695. (1) The Department of Consumer Business Services shall adopt  
23 by rule, in consultation with the Prescription Drug Affordability Board, an-  
24 nual fees to be paid by manufacturers [*that sell*] **of** prescription drugs **that**  
25 **are sold** in this state. The fees shall be established in amounts necessary to  
26 meet the costs of the department [*and the board*] in administering ORS  
27 646A.693 to 646A.695. [*The fees shall be imposed based on a manufacturer’s*  
28 *share of gross revenue from sales of prescription drugs in this state.*]

29 “(2) Fees collected under this section shall be deposited in the Pre-  
30 scription Drug Affordability Account established in ORS 705.146.



1       **“SECTION 9.** ORS 705.146 is amended to read:

2       “705.146. The Prescription Drug Affordability Account is established as a  
3 subaccount in the Consumer and Business Services Fund created in ORS  
4 705.145, consisting of moneys collected under ORS 646A.695 and moneys that  
5 may be appropriated for deposit into the Prescription Drug Affordability  
6 Account by the Legislative Assembly. Interest earned on the account shall  
7 be credited to the account. Moneys in the account are continuously appro-  
8 priated to the [*Prescription Drug Affordability Board*] **Department of Con-**  
9 **sumer and Business Services** to carry out ORS 646A.693 to 646A.695.

10       **“SECTION 10.** ORS 743.025 is amended to read:

11       “743.025. (1) An insurer shall [*include with any filing under ORS*  
12 *743.018*] **annually report to the Department of Consumer and Business**  
13 **Services, in the manner and format prescribed by the department,** the  
14 following information regarding drugs reimbursed by the insurer under [*pol-*  
15 *icies or certificates*] **health benefit plans, as defined in ORS 743B.005,** is-  
16 sued in this state **by the insurer:**

17       “(a) The 25 most frequently prescribed drugs;

18       “(b) The 25 most costly drugs as a portion of total annual spending;

19       “(c) The 25 drugs that have caused the greatest increase in total plan  
20 spending from one year to the next; and

21       “(d) The impact of the costs of prescription drugs on premium rates.

22       “(2) The department [*of Consumer and Business Services*] shall conduct a  
23 public hearing annually on prescription drug prices, information reported to  
24 the department under ORS 646A.689 and information described in subsection  
25 (1) of this section.

26       “(3) The department shall regularly update the interim committees of the  
27 Legislative Assembly related to health on the information described in sub-  
28 section (1) of this section.

29       “(4) Subsection (1) of this section applies to an insurer that issues [*poli-*  
30 *cies or certificates of health insurance*] **health benefit plans** for sale in this

1 state that include a prescription drug benefit.”.

2 \_\_\_\_\_